There are many known resistance mechanisms to VTX, such as dependencies on other antiapoptotic Bcl-2 family members, BCL-2 and BAX gene mutations, changes within the tumor microenvironment, mitochondrial metabolic reprogramming, and TP53 pathway dysfunction. The gene discussed is BCL2; the disease is neoplasm.